Fennec Pharmaceuticals Future Growth
Future criteria checks 5/6
Fennec Pharmaceuticals is forecast to grow earnings and revenue by 50.8% and 33.4% per annum respectively while EPS is expected to grow by 51% per annum.
Key information
50.8%
Earnings growth rate
51.0%
EPS growth rate
Biotechs earnings growth | 37.9% |
Revenue growth rate | 33.4% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 04 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 95 | 56 | 33 | N/A | 4 |
12/31/2025 | 71 | 26 | 33 | 43 | 6 |
12/31/2024 | 50 | 6 | 9 | 9 | 5 |
12/31/2023 | 21 | -16 | -17 | -17 | N/A |
9/30/2023 | 13 | -20 | -19 | -19 | N/A |
6/30/2023 | 7 | -26 | -21 | -21 | N/A |
3/31/2023 | 3 | -26 | -21 | -21 | N/A |
12/31/2022 | 2 | -24 | -18 | -18 | N/A |
9/30/2022 | N/A | -21 | -15 | -15 | N/A |
6/30/2022 | N/A | -17 | -12 | -12 | N/A |
3/31/2022 | N/A | -16 | -13 | -13 | N/A |
12/31/2021 | N/A | -17 | -14 | -14 | N/A |
9/30/2021 | 0 | -16 | -14 | -14 | N/A |
6/30/2021 | 0 | -18 | -17 | -17 | N/A |
3/31/2021 | 0 | -19 | -15 | -15 | N/A |
12/31/2020 | 0 | -18 | -16 | -16 | N/A |
9/30/2020 | N/A | -18 | -14 | -14 | N/A |
6/30/2020 | N/A | -14 | -11 | -11 | N/A |
3/31/2020 | N/A | -14 | -10 | -10 | N/A |
12/31/2019 | N/A | -13 | -9 | -9 | N/A |
9/30/2019 | N/A | -12 | -10 | -10 | N/A |
6/30/2019 | N/A | -13 | -10 | -10 | N/A |
3/31/2019 | N/A | -11 | -9 | -9 | N/A |
12/31/2018 | N/A | -10 | -8 | -8 | N/A |
9/30/2018 | N/A | -9 | -6 | -6 | N/A |
6/30/2018 | N/A | -9 | -6 | -6 | N/A |
3/31/2018 | N/A | -8 | -5 | -5 | N/A |
12/31/2017 | N/A | -7 | -4 | -4 | N/A |
9/30/2017 | N/A | -6 | N/A | -3 | N/A |
6/30/2017 | N/A | -4 | N/A | -3 | N/A |
3/31/2017 | N/A | -3 | N/A | -2 | N/A |
12/31/2016 | N/A | -3 | N/A | -2 | N/A |
9/30/2016 | N/A | -2 | N/A | -2 | N/A |
6/30/2016 | N/A | -2 | N/A | -2 | N/A |
3/31/2016 | N/A | -1 | N/A | -2 | N/A |
12/31/2015 | N/A | -1 | N/A | -2 | N/A |
9/30/2015 | N/A | 1 | N/A | -2 | N/A |
6/30/2015 | N/A | 2 | N/A | -2 | N/A |
3/31/2015 | N/A | 1 | N/A | -2 | N/A |
12/31/2014 | N/A | -2 | N/A | -2 | N/A |
9/30/2014 | N/A | -2 | N/A | -2 | N/A |
6/30/2014 | N/A | -5 | N/A | -2 | N/A |
3/31/2014 | N/A | 3 | N/A | -2 | N/A |
12/31/2013 | N/A | 2 | N/A | -2 | N/A |
9/30/2013 | N/A | -6 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: FRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FRX is expected to become profitable in the next 3 years.
Revenue vs Market: FRX's revenue (33.4% per year) is forecast to grow faster than the Canadian market (6.6% per year).
High Growth Revenue: FRX's revenue (33.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FRX's Return on Equity is forecast to be high in 3 years time